ESKALITH CR Drug Patent Profile
✉ Email this page to a colleague
When do Eskalith Cr patents expire, and when can generic versions of Eskalith Cr launch?
Eskalith Cr is a drug marketed by Jds Pharms and is included in one NDA.
The generic ingredient in ESKALITH CR is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eskalith Cr
A generic version of ESKALITH CR was approved as lithium carbonate by HIKMA on January 29th, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ESKALITH CR?
- What are the global sales for ESKALITH CR?
- What is Average Wholesale Price for ESKALITH CR?
Summary for ESKALITH CR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| Clinical Trials: | 13 |
| DailyMed Link: | ESKALITH CR at DailyMed |
Recent Clinical Trials for ESKALITH CR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centre for Addiction and Mental Health | Phase 4 |
| Patient-Centered Outcomes Research Institute | Phase 4 |
| Washington University School of Medicine | Phase 4 |
US Patents and Regulatory Information for ESKALITH CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jds Pharms | ESKALITH CR | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 018152-001 | Mar 29, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
